Cirio advises Alvotech in connection with its listing on Nasdaq Stockholm

Cirio advises Alvotech in connection with the triple listing of its shares on Nasdaq Stockholm in the form of Swedish depositary receipts and the offering of Swedish depositary receipts to the public in Sweden.

Alvotech is a global biotech company specializing in the development and production of biosimilars for patients worldwide. Alvotech recently announced the acquisition of Xbrane’s R&D operations in Sweden, further expanding its development capabilities and establishing a footprint in the Swedish life science sector. Alvotech is already listed on the Nasdaq Iceland Main Market in Iceland and the Nasdaq Global Market in the United States.

Cirio advised Alvotech with a team headed by Maria Arnoldsson, together with Martin Näslund, Selma Didriksson Fröjd (Equity Capital Markets and Public M&A), Carl-Axel Morvay (Banking & Finance and DCM), and Meg Lippincott (M&A).

For more information, please contact: